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Background: This study evaluated the potential of chitosan based polymeric micelles as a nanocarrier system for
pulmonary delivery of itraconazole (ITRA).
Methods: Hydrophobically modified chitosan were synthesized by conjugation of stearic acid to the hydrophilic
depolymerized chitosan. FTIR and 1HNMR were used to prove the chemical structure and physical properties of the
depolymerized and the stearic acid grafted chitosan. ITRA was entrapped into the micelles and physicochemical
properties of the micelles were investigated. Fluorescence spectroscopy, dynamic laser light scattering and
transmission electron microscopy were used to characterize the physicochemical properties of the prepared
micelles. The in vitro pulmonary profile of polymeric micelles was studied by an air-jet nebulizer connected to a
twin stage impinger.
Results: The polymeric micelles prepared in this study could entrap up to 43.2±2.27 μg of ITRA per milliliter. All
micelles showed mean diameter between 120–200 nm. The critical micelle concentration of the stearic acid grafted
chitosan was found to be 1.58×10-2 mg/ml. The nebulization efficiency was up to 89% and the fine particle fraction
(FPF) varied from 38% to 47%. The micelles had enough stability to remain encapsulation of the drug during
nebulization process.
Conclusions: In vitro data showed that stearic acid grafted chitosan based polymeric micelles has a potential to be
used as nanocarriers for delivery of itraconazole through inhalation.
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Invasive pulmonary fungal infection is major infectious
disease among immunosuppressed patients. Difficulty of
early clinical diagnosis and poor response to the com-
mon antifungal treatment result in high mortality per-
cent of patients. In the recent years many efforts done to
found an alternative drug delivery strategies for antifun-
gal agents [1,2]. Aerosolization of antifungal agents can
be used for prophylaxis against pulmonary fungal infec-
tions. High drug concentration in the site of infection,
non invasive route of administration and reduce sys-
temic toxicities are some advantages of this route of
administration [3].* Correspondence: gilani@tums.ac.ir
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reproduction in any medium, provided the orWhile amphotericin is an effective drug for treatment
of fungal infections, its adverse effects reduces its poten-
tial uses and particular interest has been focused on the
use of other antifungal drugs [4].
Itraconazole (ITRA), a triazole member, is a highly
hydrophobic drug (water solublility ~1 ng/ml at neutral
pH and 4 μg/ml at pH 1) [5] which has broad spectrum
of activity against a number of fungal species [6].
Most of potent antifungal compounds like amphoteri-
cin and azoles have very low solubility. Approaches for
achieving complete dissolution of ITRA often have dis-
advantages associated with large quantities of required
excipients [7]. These strategies may cause some limita-
tion due to the toxicity induced by high concentrations
of the drug or excipients like 2-hydroxypropyl-β-cyclo-
dexterin. Scientists have been used different strategies to
obtain technologies which required lower amounts ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Moazeni et al. DARU Journal of Pharmaceutical Sciences 2012, 20:85 Page 2 of 9
http://www.darujps.com/content/20/1/85excipients to increase the solubility. Various solid disper-
sion, emulsification and nanotechnology approaches
have been widely used to increase the solubility of itra-
conazole. Akkar and Muller prepared intravenous itraco-
nazole emulsion based on solEmuls technology. Using
this technology, the drug localizes in the interfacial leci-
thin layer of the emulsions by homogenising a hybrid
dispersion of oil droplets and drug nanocrystals in water
[8]. Also Keck and Muller used modified high pressure
hemogenisation technique (NANOEDGE) to prepare
nanocrystals of poorly water soluble drugs like itracona-
zole [9]. Some studies based on evaporative precipitation
into aqueous solution (EPAS) or spray freezing into
liquid (SFL) techniques has been used to obtain nano
itraconazole for pulmonary delivery systems [10-12].
McConville and co-workers nebulized itraconazole dis-
persion prepared by EPAS or SFL techniques and
obtained high lung concentration in animal study [11].
Self-assembled polymeric micelles (PM) are widely
investigated as an alternative choice in the development
of delivery systems for poorly water soluble drugs. PMs
are composed of different amphiphilic copolymers. The
micelles prepared by these copolymers in the aqueous
medium contain internal hydrophobic segments as drug
reservoir and external hydrophilic segments as sur-
rounding shell [13]. PMs based on chitosan, a natural
biodegradable cationic polysaccharide [14], with various
modification by different hydrophobic groups have been
used for encapsulation of different hydrophobic drugs.
Doxorubicin [15], camptothecin [16], all-trans retinoic acid
[17] and paclitaxel [18] are some hydrophobic drugs that
encapsulated by chitosan based polymeric micelles. There
are only few reports investigating the application of inhalable
polymeric micelles for delivery of all trans retinoic acid,
amphotericin B and budesunide [19-21].
The ability of the modified chitosan polymeric micelles
to improve ITRA solubility and pulmonary delivery of
ITRA were investigated in this research. In current
study, depolymerized chitosan (Mw 24 kDa) was chem-
ically modified by stearic acid and its properties were
characterized by 1HNMR and FT-IR. In vitro nebuliza-
tion parameters like fine particle fraction (FPF), nebuli-
zation efficiency (NE) and drug remained encapsulated




Itraconazole was kindly supplied by Hetero, India.
Chitosan (Medium molecular weight, 95% deacetylated)
was obtained from Primex, Iceland. Stearic acid, KCl,
NaOH, glacial acetic acid, sodium nitrite, 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC), diethyl-
ene amin (DEA), pyrene and all other solvents inanalytical and HPLC grade were provided from Merck,
Germany.
Depolymerization of chitosan
Chitosan was chemically depolymerized by sodium ni-
trite at room temperature according to Mao et al. pervi-
ous report [22]. Medium molecular weight chitosan was
dissolved in 1% acetic acid and then appropriate amount
of 0.1 M NaNO2 was added at room temperature. The
reaction was performed for 3 hrs under nitrogen gas. To
precipitate depolymerized chitosan, the pH value of re-
action was increased to about 8 with NaOH. The
obtained chitosan after centrifugation was dialyzed
(MWCO 8 kDa, Spectrum Laboratories, USA) against
deionized water for 48 hrs and finally lyophilized (Christ,
α2-4, Germany) at −80°C and 0.001 mbar pressure for
48 hrs. The molecular weight of obtained chitosan was
determined by size exclusion chromatography using
Knauer apparatus (Berlin, Germany) utilized with a PL
Aquagel-OH Mixed column (25 mm ID 8 μm at 25°C)
and a flow rate of 4 ml/min in acetate buffer medium
(0.2 M acetic acid and 0.1 M sodium acetate with pH
value of 4.6 ± 0.05) as diluent.
Synthesis and characterization of stearic acid grafted
to depolymerized chitosan
Stearic acid grafted to depolymerized chitosan was
synthesized as previously reported method [18]. Briefly,
30 ml aqueous solution of the depolymerized chitosan
was prepared at concentration of 30 mg/ml. Stearic acid
(50 mg/ml) and EDC (3 mol/mol stearic acid) were dis-
solved in absolute ethanol and the mixture was added to
the chitosan solution under stirring at 80°C for 5 hrs
and the reaction was stirred further 24 hrs at room
temperature. The mixture then was dialyzed (8 kDa
dialysis tube, Spectrum laboratories, USA) against dis-
tilled water containing 10% v/v ethanol for 48 hrs and fi-
nally the dialysis was continued against distilled water
for 2 hrs. The final product was lyophilized (Christ,
α2-4, Germany). FT-IR spectra were carried out using
Nicolet (magna IR-550, USA) spectrometer by prepar-
ation of KBr disks. Bruker FT-500 1H NMR (Bruker,
Germany) spectra were used to characterize and calcu-
late the substitution degree of modified chitosan.
Critical micelle concentration (CMC) measurement
The fluorescence technique was used to measure the crit-
ical micelle concentration (CMC) of polymeric micelles,
where pyrene was chosen as a fluorescence probe [23].
Pyrene (6×10−7M) was added to each of a series of vials
and then 10 ml of the modified chitosan solutions with
various concentrations (250 ng/ml–2 mg/ml) were added.
After 3 hrs stirring at room temperature, the fluorescence
spectrum was obtained with a spectrofluorometer (Cecil
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emission intensity of pyrene at 374 nm and 395 nm,
respectively.
Preparation and characterization of ITRA micellar
formulations
Different ITRA micellar formulations were prepared by
film hydration procedure [18,24]. Briefly, 10 mg or
20 mg of the modified chitosan and an appropriate
amount of ITRA (5% to 50% weight of the polymer)
were added to 100 ml of dichloromethane in a 250 ml
round-bottomed flask. The mixtures were sonicated
using a bath sonicator (Starsonic60, Liarre, Italy) to ob-
tain nearly clear dispersions, then the solvents were
removed using a rotary evaporator (Buchi Rotavapor
R-124, Buchi, Switzerland) at a reduced pressure at 60°C
and 120 rpm to obtain thin films. To remove residual
amount of the solvents, the films were placed in a vac-
uum oven (Memmert, VO400, Germany) at 40°C over-
night. The dried thin films were hydrated with 10 ml of
deionized water (Direct-QW 3UV, Millipore, France) for
45 min at 50°C and 120 rpm.
Finally, the suspensions were sonicated for 2 min by a
probe sonicator (UP400S, hielscher ultrasound technol-
ogy, Germany) in ice-bath.
To measure ITRA entrapment efficiency (EE), the final
dispersions were filtered through 0.22 μm DuraporeW fil-
ters (MILLEXW-GV, Millipore, Ireland) and specified
amounts of the filtrates were added to 8 ml of DMF:water
(80:20). Measurement of ITRA concentration was carried
out using an HPLC system (Waters 600E, Millipore, USA)
equipped with a C18 column (4.6 mm×150 mm, 5 μm,
teknokroma, Spain). The mobile phase consisting of aceto-
nitrile, water, and diethyl amine (60:40:0.05, v/v) was deliv-
ered at a flow rate of 1 ml/min, while UV detection was
utilized at 260 nm. The injection volume was 20 μl. The
drug EE was calculated as a percentage value by dividing
the amount of ITRA entrapped in the micelles to the ini-
tial amount of ITRA. The drug loading (DL) value
obtained as percent ratio of the weight of ITRA loaded in
the micelles to the total weights of the micelles. The par-
ticle size distribution and the zeta potential of polymeric
micelle formulations were measured by a Zetasizer
(Nano-ZS, Malvern Instruments Ltd., UK).
Nebulization efficacy of ITRA-loaded polymeric micelle
formulations
Nebulization of the polymeric micelle formulations were
done with an Air-jet nebulizer (HudsonW, UK). 5 ml of
each formulation was placed into the nebulizer which
was connected to the mouthpiece of a Twin stage impin-
ger (TSI; Copley, UK) containing DMF/distilled water
(3/1 vol.) in the stages 1 and 2. After connecting the TSI
to a vacuum pump, the air flow (28.3 l/min) wasadjusted through the apparatus. Nebulization was ended
when no aerosol was produced. After nebulization, the
two chambers of TSI, its mouthpiece and the nebulizer
were washed separately with DMF/distilled water (3/1
vol.). The total amount of the ITRA recovered from the
two stages of TSI was defined as the emitted dose. Neb-
ulization efficiency (NE) was calculated as the percent-
age of the ratio of the emitted dose to the initial amount
of the drug poured into the nebulizer. Fine particle frac-
tion (FPF) was determined by dividing the amount of
ITRA recovered from the lower stage of TSI (fine par-
ticle dose; FPD) to the emitted dose and expressed as
percentage. Drug remained encapsulated in the micelles
(DRE) at the end of the nebulization process was deter-
mined with minimum change in the procedure which
was used for determination of the nebulization effi-
ciency. Briefly, distilled water was located in the upper
and lower chambers of TSI. After collection of the nebu-
lized micelles, half of the dispersion was diluted four
times with DMF to determine the total amount of the
drug emitted from the nebulizer. The other half was fil-
tered through a syringe filter (0.45 μm) to separate the
non-encapsulated drug. Then, the filtrate was diluted
four times with DMF. The percent of ITRA remained in
the micelles during nebulization was calculated by divid-
ing the concentration of ITRA in the filtrate to the total
amount of the drug emitted from the nebulizer, ex-
pressed as percentage.
In vitro release study
The in vitro release profile of ITRA from micelles were
carried out by dialysis method [16].Briefly, 5 ml of each
micellar formulation( 5% drug percent ratio with 1 and
2 mg/ml of polymer concentration) was placed in a dia-
lysis tube (Mwco 8 kDa, Spectrum laboratories, USA)
which was immersed in 20 ml of PBS (pH 7.4) in a bath
shaker at 37°C under mild agitation. At predetermined
time intervals, the whole medium was taken out and the
same volume of fresh medium replaced. The amount of
ITRA released from the micelles was determined by the
HPLC method which has been described before.
In vitro Anti fungal activity
ITRA minimal inhibitory concentration (MIC) was deter-
mined by broth macro dilution method in Sabouraud
dextrose broth medium. The antifungal efficacy of two
drug loaded polymeric micelle formulations prepared
using 50% and 5% initial drug amount per mg of polymer
weight at 2 mg/ml initial polymer concentration were
tested against dissolved ITRA in DMSO. MIC was defined
as the minimal concentration of the antifungal agent inhi-
biting visible growth of the microorganism. The concen-
tration of ITRA used for MIC determination of each fungi
varied from 4 to 0.03 μg/ml. In each tube containing 1 ml
Figure 1 The GPC spectrum of depolymerized chitosan.
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of fungal organisms (Candida albicans, Aspergillus niger,
Aspergillus fumigatus) was added as an inoculum. The
tubes with total volume of approximately 1 ml in each
were incubated at 25°C for 72 h. The incubation time for
Candida albicans was 48 h. All the tests were repeated
three times.
Statistical analysis
Data for all measurements were considered as mean ±
standard deviation (S.D.) of three separate experiments.
One-way analysis of variance (ANOVA) followed byFigure 2 FT-IR spectra of chitosan (A) and depolymeriezed chitosan-sTukey post hoc test were used for statistical analysis of
the results. The significance level was set at p < 0.05.
Results and discussions
Depolymerization of chitosan
Depolymerization of chitosan by NaNO2 and H2O2 were
previously investigated [22,25]. In this study, NaNO2
was used and the obtained depolymerized chitosan
showed good water solubility. Figure 1 shown gel perme-
ation chromatography (GPC) spectrum of depolyme-
rized chitosan. The data of GPC revealed that the
depolymerized chitosan had number average moleculartearic acid (B).
Figure 3 HNMR spectra of depolymerized chitosan grafted to stearic acid in DMSO-d6.
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(Mw) of 14984 K and Z-average molecular weight of
24378 K with a narrow molecular mass distribution with
polydispersity index (Mw/Mn) of 1.56, indicating a
monodispersed chain length.Figure 4 Intensity ratio plot of 1374/1395 versus concentration of chSynthesis and characterization of stearic acid grafted
to depolymerized chitosan
The synthesis yield was about 41%. To confirm structural
change and binding of stearic acid to the depolymerized
chitosan, FT-IR and 1HNMR analysis were used.itosan-stearic acid.
Table 1 Physicochemical properties of the polymeric micelle formulations prepared by film hydration method (mean±SD, n=3)
Polymer concentration
DAa 1 mg/ml 2 mg/ml
EE% b Conc. c DL d Size (nm) Z.Pe (mv) EE% Conc. DL Size (nm) Z.P (mv)
50% 6.45±0.1 32.25±1.6 3.12±0.05 154.25±1.1 60.25±1.9 4.32±0.2 43.2±2.3 4.13±0.21 189.65±1.3 34.2±1.6
16.6% 9.94±0.6 16.51±1.1 1.62±0.10 125.75±1.7 63.25±1.7 6.03±0.4 20.03±1.4 0.99±0.07 176.71±2.6 45.31±1.8
5% 50.66±3.9 25.33±1.9 2.47±0.18 146.95±1.9 71.62±1.1 37.16±2.9 37.16±2.9 1.82±0.14 196.51±1.3 52.95±1.1
Blank micelle - - - 121.37±1.1 74.28±1.8 - - - 168.31±1.2 58.34±1.7
a Drug amount per mg of polymer weight, b Entrapment efficiency, c Drug concentration in formulation(μg/ml), d Drug loading, e Zeta potential.
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acid-chitosan spectrum showed some changes according
to the binding between stearic acid carboxylic group and
chitosan amine (Figure 2). The increase of the C-H
absorption at 2851.9 cm-1 indicated the presence of
stearic acid. Stearic acid-chitosan showed two absorptions
at 1700.6 cm-1 and 1739.3 cm-1 that ascribed to the car-
bonyl zone which related to the chemical and physical
binding of stearic acid and chitosan. The purity of the
synthesized polymers has been studied by using FT-IR
spectrum of the samples, according to the similar studies.
After dialysis of stearic acid grafted to the chitosan
(against distilled water containing 10% v/v ethanol for
48 hrs) the free stearic acid removed from synthesized
product. To confirm this result, the results obtained from
washing synthesized product with warm ethanol on the
0.45 μm filter were compared and shown similar results as
well as the dialysis method. Considering the low solubility
of stearic acid in water, the trace of free stearic acid mole-
cules remained in the aqueous media might find its way to
the core hydrophobic segments of the micelles, the place
that is thermodynamically more suitable for these mole-
cules. But it is possible a very low percent of free stearic
acid intercalate between natural polymer chain and cannot
remove completely. The FT-IR spectrum after repeat of
synthesis procedures were same and shown the suitability
and repeatability of our procedure.. All of these results
indicated the formation of amide band and confirmed the
conjugation of chitosan to stearic acid.
The 1H-NMR spectra of the depolymerized chitosan
grafted to stearic acid showed in Figure 3. compared
with chitosan 1H-NMR spectrum the triplet signals at
0.85 ppm, due to the terminal CH3 protons of stearic
acid. The new peak at 1–1.5 ppm was corresponded to
the CH2 chain of acyl chain. These results exhibited that
stearic acid was linked to depolymerized chitosan.Table 2 Aerosolization parameters of ITRA loaded polymeric m
DAa RDb(%) ED (μg) FPD (μ
50% 84.05±3.23 197.5±3.53 94.2±3
16.6% 80.15±1.20 92.25±4.59 39.7±3
5% 84.9±1.97 171±7.07 76.1±1
aDrug amount per mg of polymer weight, bRecovered Dose.The degree of substitution of the prepared modified
polymer was about 61%, calculated by 1HNMR method.
To calculate the degree of substitution, the area under
the triplet signals at 0.85 ppm was compared to the area
under the peaks at 2–4 ppm, which were related to
hydrogens of the depolymerized chitosan.
Critical micelle concentration (CMC) measurement
Many researches exhibited that polymeric micelles gen-
erally have lower CMC than low molar weight surfactant
micelles. When pyrene is in polar media, its emission is
weak and only there is an enhancement in the intensity
of I1 (the emission intensity at 374 nm), whereas no
effect is seen on that of I3 (the emission intensity at
395 nm). By formation of micelles in an aqueous solu-
tion, pyrene entered to the hydrophobic core of the
micelles and the intensity of the third highest vibrational
band at 395 nm (I3) starts to strongly increase. There-
fore, the changes in the intensity ratio of I1/I3 were used
to determine the CMC of stearic acid-depolymerized
chitosan micelles. The plot of the intensity ratio of I1/I3
versus the logarithm of the polymer concentration is
exhibited in Figure 4. The interception of the two
straight lines was considered as CMC of the polymer
and was observed at 1.58×10-2 mg/ml of the polymer.
This value was similar to the CMC values that were
reported in the literature [26,27].
Entrapment efficiency of ITRA in the polymeric micelle
formulations
The amount of drug entrapment in polymeric micelles
by physical procedure is depended on several factors, in-
cluding physicochemical properties of drug and block
copolymers [28]. In this study, a long fatty acid chain
(stearic acid) was used to entrap itraconazole as a highly
hydrophobic molecule.icelles at 2 mg/ml polymer concentration (mean±SD, n=3)
g) FPF (%) DRE (%) NE (%)
.64 47.7±0.98 89.4±1.5 89.9±0.99
.20 43.0±1.32 95.3±1.1 88.9±0.11
.55 44.5±2.73 98.0±0.6 89.5±0.27
Figure 5 In vitro ITRA release profile from micelles prepared by different polymer concentration (♦) 2mg/ml and (■) 1mg/ml with same
drug percent ratio (5%).
Table 3 Minimal inhibitory concentration of free ITRA
(dissolved in DMSO) and ITRA loaded in polymeric
micelles against three fungal strains (mean±SD, n=3)






Micelles 5%* 0.5 2 1
Micelles 50%** 0.5 2 1
DMSO 0.5 2 1
*, Micelles prepared by using 5% initial drug amount per mg of polymer
weight at 2 mg/ml initial polymer concentration.
**, Micelles prepared by using 50% initial drug amount per mg of polymer
weight at 2 mg/ml initial polymer concentration.
Moazeni et al. DARU Journal of Pharmaceutical Sciences 2012, 20:85 Page 7 of 9
http://www.darujps.com/content/20/1/85The polymeric micelles prepared in this study could
entrap up to 43.2±2.27 μg/ml of ITRA (Table 1), more
than 1000-fold relative to its aqueous solubility. It
seemed that in the film hydration method good disper-
sion of the drug molecules through very thin polymer
film helped to efficiently entrap ITRA. The data showed
that by increasing in drug percent ratio in both con-
centrations of polymer the EE% decreased because
the initial amount of added drug was high, however
the high amount of ITRA encapsulated at both poly-
mer concentration at 50% weight ratio of drug to the
polymer.
The highest entrapment efficiency obtained by this
procedure (37.16±2.91) when the polymer concentration
was high (2 mg/ml) and the drug was used at the lowest
percentage.
Particle size distribution measurements
The molecular weight of polymer and the properties of
hydrophobic segment and drug are the most important
factors influencing the size of polymeric micelles [29]. In
all formulations, the mean diameters of the ITRA loaded
polymeric micelles were between 120 to 200 nm with
polydispersity index ranged between 0.18-0.22 (Table 1).
The size of micelles increased significantly with increas-
ing the polymer concentration. Data showed that signifi-
cant change has been made with increasing ITRA to
polymer weight percent from 5% to 50%, while keeping
the polymer concentration constant. The more ITRA
entrapped into the blank micelles, the more zeta poten-
tial was decreased (Table 1). Generally zeta potential
exhibited reverse relation with the amount of ITRA
entrapped into the micelles.Nebulization of ITRA loaded polymeric micelles
For evaluation of nebulization efficacy, ITRA loaded
polymeric micelle formulations were aerosolized at 28 l/
min through a twin stage impinger. FPF (ratio of
aerosolized particles < 6.4 μm) and the value of nebuli-
zation efficiency of the formulations are exhibited in
Table 2. The results showed that polymeric micelles with
different particle size had the same aerosolization
properties.
These results are in accordance with our previous
work on amphotericin B polymeric micelle formulations
[20]. Also some reports showed that physical properties
of the nebulization medium have an important role in
the size distribution of the aerosolized droplets and dro-
plets aerosolized from medium with similar properties
showed the same size distribution [30]. To calculate the
resistance of polymeric micelle formulations against
shear force that occur in the air jet nebulizer and to
evaluate the capability of these formulation to remained
ITRA encapsulated during nebulization, the encapsula-
tion efficiency of the formulations after nebulization
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formulations were stable during nebulization process
(Table 2). These data suggested that polymeric micelles
have good stability against shear force induced in air
jet nebulizer. Similar results were observed after
nebulization of amphotericin B loaded polymeric
micelles [20].
In vitro release study
In vitro release profile of ITRA from formulation con-
taining 5% drug amount per mg of polymer weight at 1
and 2 mg/ml polymer concentration exhibited in
Figure 5. The release profiles showed two phase pattern.
Over the first 12 hrs about 49% of the drug released
from both micellar formulations. This relative rapid
release behavior may be due to the drug molecules
which adsorb on the outer surface of the micelles or
intercalate between hydrophilic polymers. Total amount
of the drug released after 60 hrs. Similar release pattern
from polymeric micelles reported in some other studies
[31,32]. As it shown in Figure 5 and results obtained
from statistical analysis there is no significant difference
between release profile of formulations.
In vitro antifungal activity
Table 3 showed the MIC of ITRA in different formu-
lations for 3 fungal strains. The results showed that
ITRA loaded polymeric micelle formulations had the
same MIC values as dissolved ITRA in DMSO. The
antifungal activity of the two micellar formulations
was similar probably due to close proximity of the
size distribution data of the formulations. The data
obtained from antifungal experiments revealed that
chitosan based polymeric micelles could be used for
solubilization of ITRA in aquouse media with anti-
fungal activities equal to that of organic based ITRA
solutions. The micelles without drug had no signifi-
cant antifungal activity.
Conclusion
Through grafting stearic acid onto depolymerized
chitosan, the modified polymer can form micelles in
nano size range. The data showed that stearic acid as
the hydrophobic core of the micelles could entrap ITRA
and increase the solubility of the drug. The size distribu-
tion of all formulations was mono modal and ranged
from 120 nm to 200 nm. In vitro nebulization study of
the ITRA loaded formulations showed that the stearic
acid-chitosan based polymeric micelles had adequate
capability as nanocarriers to deliver ITRA and can re-
main their stability during nebulization.
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